Implantica Inc. Shs A Swedish Depositary Receipt Repr 1 Sh A
62.30
SEK
0.00
(0.00%)
ISIN
SE0014855029
Return %
Stock
S&P 500
1Y
7.97
14.20
3Y
255.59
81.12
5Y
-22.51
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Peter Forsell
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Aeulestrasse 45 Vaduz VA Liechtenstein 9490
- IPO Date
- Sep 21, 2020
- Website
- implantica.com
- Similar Companies
- Business
- Implantica AG (IMP A SDB:STO) develops and commercializes innovative medical implants leveraging advanced eHealth and wireless energizing platform technologies to address unmet needs in gastrointestinal surgery and urology. The company's lead product, RefluxStop, is a passive CE-marked implant for preventing gastroesophageal reflux disease (GERD) that has demonstrated excellent long-term outcomes in a 5-year clinical study; it is commercially available across Europe, including Germany, the United Kingdom, Switzerland, Spain, Italy, France, Austria, Sweden and Norway. Implantica's development pipeline features prioritized products such as AppetiteControl, a remote-controlled implant for obesity treatment via appetite suppression; UriControl, a device addressing urinary incontinence in men and women; UriRestore, enabling on-demand urination for patients with spinal cord injuries or multiple sclerosis; and e-InVivo, a sensor-based eHealth platform for remote health monitoring and treatment control inside the body, all supported by over 1,000 patent cases. Founded in 2015 and headquartered in Zug, Switzerland, with additional operations in Liechtenstein and Germany, Implantica targets a global patient population affected by conditions like GERD impacting over 400 million people worldwide, while pursuing U.S. market entry through FDA Premarket Approval (PMA). In recent developments, the company published landmark 5-year RefluxStop clinical results in July 2025 confirming sustained efficacy, ramped up production with an order for 10,000 units in September 2025 ahead of anticipated FDA approval and U.S. launch, and reported 3% net sales growth to €1.5 million in the first nine months of 2025 alongside a strong liquidity position of €56 million with no interest-bearing debt. These advancements underscore Implantica's strategic focus on scaling commercialization, initiating a randomized controlled trial, and navigating regulatory milestones for broader adoption.